Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antithrombotic therapy after atrial septal defect closure
ChiCTR2000035713Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in atrial septal defect (ASD) and brain infarction comparing Bayaspirin + Plavix with High-dose Bayaspirin monotherapy (2 arms). Primary endpoints: Area of new cerebral infarction lesions and Adverse events. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
Cartiaclopidogrel
03
Conditions
atrial septal defect (ASD)brain infarction
Beyond the preview
Go deeper on ChiCTR2000035713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035713.